紫杉醇作为一线药物在卵巢癌化疗中的应用  

The Treatment of Ovarian Cancer with Paclitaxels in first Line Chemotherapy

作　　者：赵营[1] 黄守松 杜佩妍[1] 

机构地区：[1]广州医学院附属肿瘤医院妇瘤科,广东广州510095

出　　处：《国际医药卫生导报》2007年第15期101-104,共4页International Medicine and Health Guidance News

摘　　要：目的探讨紫杉醇（安泰素）联合铂类药物（TP方案）和国产紫杉醇（紫素）联合铂类药物（PTP方案）以及环磷酰胺加铂类药物和阿霉素（CAP方案）作为一线药物治疗上皮性卵巢癌的疗效及毒性。方法对1997年7月～2005年12月采用TP、PTP及CAP化疗方案作为一线药物治疗的64例卵巢癌患者进行回顾性分析。TP组27例、PTP组22例、CAP组15例。结果TP组有效率为81．5％、PTP组有效率为63．6％、CAP有效率为53．3％。三组相比较，TP组和PTP组的一线用药有效率均高于CAP方案（P〈0．05）。结论TP和PTP作为一线用药的疗效均优于CAP，TP与PTP在疗效及副作用上无明显差异（P〈0．05）。Objective To study the effect and toxicities of paclitaxel（USA） combined with platinum（TP） and paclitaxel（Chinese） combined with platinum （PTP） in the first line treatment of epithelial ovarian cancer, and to compare with the combination of cyclophosphamide, adriamycin and platinum（CAP）.Methods A retrospective analysis about the treatment of ovarian cancer with TP, PTP and CAP from 1997 to 2005 was done, including 27 cases in TP, 22 cases in PTP and 15 eases in CAP group. Results The response rate （RR） in TP, PTP and CAP was respectively 81.5%, 63.6% and 53.3%. Compared the RR of three groups, TP and PTP group were higher than CAP group （P〈0.05）. Conclusion In the first line chemotherapy methods of ovarian cancer, TP and PTP were clinically more effective than CAP. And there was no apparent difference in the effect and toxicity for two kinds of paclitaxel.

关 键 词：卵巢上皮癌 化疗 紫杉醇 

分 类 号：R737[医药卫生—肿瘤]